


































HIPK2 is a potential tumor suppressor gene; it is a 
nuclear serine/threonine kinase that acts as co-
repressors for transcription factors [1] and is considered 
a central switch in the targeting of cells toward 
apoptosis upon genotoxic stress by phosphorylating 
tumor suppressor p53 at serine 46 (Ser46) [2,3]. The 
p53Ser46 modification triggers irreversible apoptosis by 
determining p53-dependent promoter selection [4]. 
HIPK2 contributes to p53 apoptotic activation by 
inducing Ser46 phosphorylation but also lysine 382 
(Lys382) acetylation [2,3,5]. Thus, we found that 
HIPK2, through repression of Nox1 gene, strongly 
regulates p53 acetylation/deacetylation balance that 
along with (p)Ser46 is important for full p53 apoptotic 
activity [6]. A major determinant of tumor progression 
and cancer therapy is the ability of cancer cells to 




































function. Understanding how aberrant signalling within 
tumors can interfere with p53 apoptotic activation is 
therefore of particular importance. Although mutations 
in the p53 gene are detected in ∼50% of human cancers, 
indirect mechanism also leads to p53 inactivation [7]. 
Previous work has shown that knock-down of HIPK2, 
mainly by siRNA, leads to loss of p53 function, reduced 
apoptotic drug-response and increased tumor 
progression [8]. Therefore, an intact HIPK2 function is 
crucial for the apoptotic activation of wtp53 in tumors. 
 
A physiological condition that inhibits HIPK2 functions 
in solid tumor is hypoxia which is a hallmark of tumor 
progression and failure of tumor therapies. Hypoxia-
induced ubiquitin ligases such as Siah2 [9] or p53 
targets MDM2 [10] and Siah1 [11] trigger HIPK2 
degradation strongly affecting drug-induced p53 
apoptotic activity. The key molecule expressed under 
hypoxia is hypoxia inducible factor-1 (HIF-1), a 
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HIF-1β subunit, constitutively expressed in cells, and 
the oxygen-sensitive HIF-1α subunit. Under normal 
oxygen levels, HIF-1α is hydroxylated at key proline 
residues facilitating interaction to von Hippel-Lindau 
protein (pVHL) which allows HIF-1α proteasomal 
degradation. Under hypoxic conditions, prolyl 
hydroxylation is inhibited, HIF-1α accumulates, 
dimerizes with HIF-1β forming the active HIF-1 
complex for regulation of transcription of several genes 
involved in many aspects of cancer progression, 
including angiogenesis, metabolic adaptation, apoptosis 
resistance, invasion and metastasis [12]. HIF-1α 
synthesis and transactivation can also be activated by 
non-hypoxia-mediated mechanisms such as genetic 
alterations in a variety of cancer types. In this regard, 
we have shown that HIPK2 represses the HIF-1α 
transcription, thus, HIPK2 knock-down leads to HIF-1α 
upregulation with induction of a “constitutive hypoxic” 
phenotype [13]. Increased HIF-1α levels have been 
shown to be associated with increased resistance to 
conventional chemo- and radiotherapy in many solid 
tumors and play a negative role in patient prognosis. 
Thus, the downregulation of the activity of HIF-1α 
could have an immediate effect on its target genes 
contributing to blocking tumor angiogenesis, glycolysis 
and tumor growth and also improve the efficacy of 
classical therapies [14]. 
 
HIF-1α interacts with p53 and stimulates p53 
transcriptional activity [15] although it antagonizes p53-
mediated apoptosis [16]. Here we report a previously 
unknown regulatory circuitry between HIF-1α, HIPK2 
and p53 apoptotic activity as the molecular mechanisms 
underlying HIPK2 regulation by HIF-1α have never 
been addressed. 
 
RESULTS AND DISCUSSION 
 
We first analyzed the effect of HIF-1α on DNA-
damage-induced p53 apoptotic activation by using an ex 
vivo experimental model consisting of cell populations 
derived from explants of prostate cancer patients 
characterized by stabilized HIF-1α protein in normoxia 
(“constitutively hypoxic” phenotype) and associated 
with bad prognosis (namely C27 cells), and cell 
populations with a phenotype negative for HIF-1α 
expression under aerobic condition associated with 
good prognosis (namely C38 cells) [17]. The presence 
of HIF-1α overexpression at mRNA (Figure 1A) and 
protein level (see Figure 2F) in C27 cells led to a 
marked inhibition of drug-induced luciferase activity of 


















































tary Figure 1a) which is a well established target of p53-
Ser46 modification and of p53 apoptotic activity [4]. 
Thus, in response to X-ray or to the radiomimetic drug 
bleomycin, both Ser46 phosphorylation, the cleavage of 
the  apoptotic  marker  PARP,  and  p53  apoptotic  gene  
Figure  1.  HIF‐1α  antagonizes  p53  apoptotic  activity.  (A)
Luciferase  assay  in  C38  and  C27  prostate  cancer  cells  showed
significantly  higher  HIF‐1α‐luc  promoter  activity  in  C27  cells.
*P=0.0159. (B) Luciferase assay of p53AIP1‐luc reporter in C38 and
C27  prostate  cancer  cells  after  bleomycin  (Bleo)  treatment
showing impairment of p53 transcriptional activity in C27 cells. (C)
Immunoblot  of  C38  and  C27  cells  after  40  Gy  X‐irradiation
revealed  PARP  cleavage  and  Ser46  phosphorylation  only  in  C38
cells. Blot image was cut and pasted. (D) RT‐PCR analysis of p53
apoptotic target genes in C38 and C27 prostate cancer cells after




(ADR)  treatment  showed  abolishment  of  (p)Ser46  after  HIF‐1α‐
Flag overexpression. (G) Luciferase assay of p53AIP1‐luc reporter in
C27  cells  showed  induction  of  luciferase  activity  after  HIF‐1α
silencing with siRNA. 
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cells, compared to C38 cells negative for HIF-1α 
expression under aerobic condition (Figure 1C, 1D). 
Two lines of evidence indicate that the p53 apoptotic 
defect in C27 cells is due to stabilization of HIF-1α 
rather than to alternative mechanism of drug resistance 
or impairment of p53 downstream signalling. First, 
increasing HIF-1α levels in C38 prostate and RKO 
colon cancer cells by protein overexpression also 
conferred resistance to X-ray- or to drug-induced p53 
transcriptional activity (Figure 1E  and Supplementary 
Figure S1b, S1c) and inhibited Ser46 phosphorylation 
(Figure 1F). Second, loss of HIF-1 function by HIF-1α 
knock-down, restored the sensitivity to X-ray-induced 
p53AIP1-luciferase activity in C27 cells (Figure 1G). 
These results show that HIF-1α levels are relevant to 
the p53-mediated cellular response because they 
antagonized drug-induced p53Ser46 apoptotic 
transcriptional activity. 
 
P53Ser46 phosphorylation is triggered by several 
kinases including HIPK2 whose knock-down strongly 
inhibits p53 apoptotic activity [5,8]. Therefore, an intact 
HIPK2 function is crucial for the apoptotic activation of 
wtp53 in tumors. We first evaluated whether HIF-1α 
affected HIPK2 mRNA expression. RT-PCR analyses 
of ADR-treated RKO cells showed that endogenous 
HIPK2 messenger RNA levels were not altered by HIF-

























HIF-1α inhibited the drug-induced p53(p)Ser46 (Figure 
1F), arguing for HIF-1α-mediated regulation of HIPK2 
at the post-transcriptional level. We then performed 
experiments under conditions of HIF-1α and HIPK2 
overexpression. Expression of increasing amounts of 
HIF-1α in 293 cells correlated with abolishment of 
HIPK2 protein levels (Figure 2A). A test for protein 
degradation showed that HIF-1α-induced HIPK2 
downregulation in prostate C38 cells could be rescued 
by cell treatment with the proteasome inhibitor MG132 
(Figure 2B), confirming a HIPK2 post-translational 
regulation. Thus, HIF-1α co-overexpression did not 
affect HIPK2 gene transcription in RKO colon cancer 
cells (Figure 2C). We next analysed these issues in C27 
prostate cancer cells whereas HIF-1α upregulation 
antagonizes drug-induced p53Ser46 apoptotic 
transcriptional activity, suggesting that they should 
harbour reduced HIPK2 levels. Indeed, western blot 
analysis showed reduced HIPK2 protein levels in 
“constitutively hypoxic” C27 cells compared to the C38 
cells with a phenotype negative for HIF-1α expression 
under aerobic condition (Figure 2D), while the HIPK2 
mRNA levels were comparable expressed between the 
two cell lines (Figure 2E). Was the reduction of HIPK2 
levels caused by HIF-1α upregulation? We addressed this 
issue by silencing of HIF-1α with siRNA that indeed 
rescued HIPK2 protein levels in C27 cells (Figure 2F). 


























(A)  HIF‐1α‐Flag  (4,  6,  and  8  μg)  and  HIPK2‐GFP  (4  μg)
expression  vectors  were  co‐transfected  in  293  cells  where
immunoblot analyses showed that increased amounts of HIF‐













www.impactaging.com                    35                                         AGING, January 2011, Vol.3 No.1How could HIF-1α inhibit HIPK2? First, being a 
transcription factor, HIF-1 might promote the 
expression of target genes that induce HIPK2 
degradation. Alternatively, HIF-1 might directly interact 
with and regulate HIPK2. To discriminate between 
these two scenarios, exogenous HIPK2 and HIF-1α 
proteins were co-expressed in 293 cells for co-immuno-
precipitation analysis. We found absence of interaction 
between HIPK2 and HIF-1α (Supplementary Figure 
S2a), suggesting rather a transcription-dependent 
regulation. The latter hypothesis was evaluated by the 
use of a HIF-1α mutant encoding the dominant negative 
form of HIF-1α without DNA binding and trans-
activation domains (HIF-1αDN) [18]. The results 
unequivocally showed that the HIF-1αDN mutant could 






































Previous studies showed that HIF-1 may induce p53 
transcriptional activity [15], although not the apoptotic 
one [16], and that p53 target genes such as MDM2 
[10] or Siah1 [11] may trigger HIPK2 degradation 
under hypoxia. Moreover, the putative HIF-1 target 
WD40-repeat/SOCS box protein WSB-1 [19] has been 
shown to trigger HIPK2 degradation [20]. To evaluate 
whether p53 transcriptional activity plays a role in 
HIF-1α-induced HIPK2 degradation, HIF-1α and 
HIPK2 proteins were co-expressed in H1299 lung 
cancer (p53 null) cells and assayed for western 
immunoblotting. In the absence of p53, HIF-1α was 
still able to reduce HIPK2 protein levels 
(Supplementary Figure S2c). We  conclude that HIF-
1α inhibits HIPK2 via transcriptional upregulation of 
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reduces both HIPK2 protein levels and p53 apoptotic 
activation. The direct effect of HIF-1α on HIPK2-
induced p53 activation was then analysed under 
conditions of proteins overexpression. The luciferase 
assay performed in 293 cells clearly showed that the 
positive effect of HIPK2 on endogenous p53 apoptotic 
transcriptional activity was eliminated by HIF-1α co-
expression that indeed abolished HIPK2 levels (Figure 
3A). The abolishment of p53 transcriptional activity 
was confirmed in vivo in RKO cells by RT-PCR 
analysis (Figure 3B). We then performed experiments 
with p53 overexpression in H1299 cells. HIF-1α 
abolished the HIPK2 additive effect on p53-induced 
Noxa-luc activity (Figure 3C, compare lane 3 with lane 
2 and lane 4 with lane 3), while HIF-1αDN mutant 






































suggesting that HIF-1α is acting on HIPK2 function. To 
finally demonstrate this issue, the transcriptional activity 
of a p53S46D mutant, which expresses constitutive Ser46 
phosphorylation, was not inhibited by HIF-1α (Figure 
3C, compare lane 7 with lane 6), confirming that HIPK2 
is indeed the target of HIF-1α-induced p53 regulation. 
Next, we investigated the effect of HIPK2 inhibition on 
apoptosis. The results clearly showed that HIF-1α 
significantly counteracted HIPK2-induced cell death 
(Figure 3D). Finally, HIF-1α overexpression led to 
marked reduction of ADR-induced p53AIP1-luc activity 
in RKO cells, while the HIF-1α-DN mutant did not show 
such effect (Figure 3E), as also tested by in vivo by RT-
PCR analyses (Figure 3F). These results recapitulate the 
negative effect of constitutive hypoxic phenotype on 
HIPK2-induced p53 apoptotic transcriptional activity and 
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in vitro and in vivo by acting on prolyl hydroxylation 
and VHL interaction [21]. We also showed that zinc 
inhibits MDM2 ubiquitin ligase activity, counteracting 
MDM2-induced p53 degradation and re-establishing 
HIPK2 stability [22]. Restoration of wtp53 function is 
decisive for the success of anti-tumor therapies and for 
tumor regression in vivo [23,24]. Therefore, zinc 
treatment of tumor cells with HIF-1α upregulation and 
that retain wild-type p53 should result in (i) 
reconstitution of HIPK2-induced p53Se46 
phosphorylation, (ii) activation of p53-apoptotic genes 
and (iii) restoration of drug-induced apoptosis. The 
HIPK2-induced p53(p)Ser46 in RKO cells, abolished 
by HIF-1α co-expression, was completely re-
established by zinc treatment that, as expected, 
concomitantly rescued the HIF-1α-induced HIPK2 
downregulation (Figure 4A). The HIPK2-induced p53 
transcription of p53AIP1-luc reporter, inhibited by HIF-
1α, was strongly recovered by zinc treatment (Figure 
4B, compare lane 4 with lane 3), while the inhibition 
triggered by a HIF-1α expression vector with prolyl 
mutations P402A and P564A (HIF-1αP/A) was not 
rescued by zinc (Figure 4B, compare lane 6 with lane 
5), in agreement with our findings that the HIF-1αP/A 
mutant is not downregulated by zinc [21]; finally, the 
HIF-1αDN mutant did not inhibit the HIPK2-induced 
p53AIP1-luc activity (Figure 4B, compare lane 7 with 
lanes 5 or 3) that was rather superinduced by zinc 
(Figure 4B, compare lane 8 with lane 7), suggesting 
inhibition of endogenous HIF-1α by the HIF-1αDN 
mutant. The positive effect of zinc on rescue of 
HIPK2/p53 activity in the presence of HIF-1α 
upregulation was confirmed by in vivo RT-PCR 
analysis of p53 apoptotic target genes (Figure 4C) and 
by cell death analysis (Figure 4D). 
 
The above results demonstrate that zinc treatment 
counteracts the HIF-1α-mediated inhibition of HIPK2, 
allowing restoration of p53 response to antitumor 
therapies. Thus, this issue was addressed in C27 
prostate cancer cells in which both HIPK2 and p53 are 
disabled by constitutive HIF-1α upregulation. The 
results clearly showed that zinc restored (i) the 
endogenous p53 transcriptional activity in response to 
X-irradiation, (ii) the in vivo transcription of p53 target 
genes in response to drug and (iii) the cell death to 
genotoxicity (Supplementary Figure S3a-c), again 
implicating the HIF-1α/HIPK2 circuitry as shown by 
rescue of endogenous HIPK2 stability by zinc 
(Supplementary Figure S3d). These results are 
consistent with several observations by us showing that 
zinc supplementation can increase tumor response to 
drugs and counteract the negative effect of hypoxia, by 
acting on several interconnected signalling molecules 
such as HIPK2, HIF-1 and p53 [25]. 
 
Restoration of HIPK2 activity was finally monitored by 
chromatin immunoprecipitation assay as HIPK2 is able 
to modulate the transcription of several factors involved 
in cell survival and apoptosis [1]. The results showed 
that HIPK2 recruitment onto target genes such as Bcl-2 
[26] or CYP1B1 [9] was present in basal condition only 
in C38 cells compared to the C27 cells where it was 
instead rescued by zinc treatment (Supplementary 
Figure S4). HIPK2 recruitment onto Bcl-2 promoter is 
again indicative of functioning p53 as HIPK2 has been 
shown to be involved in the transcriptional repression of 
Bcl-2 promoter exerted by p53 [26]. 
 
HIF-1α stabilization due to low oxygen or because 
genetic alterations is responsible of increased chemo-
resistance and tumor cell viability in part due to 
inhibition of p53 apoptotic gene transcription [10]. The 
discovery here of the HIF-1α/HIPK2 circuitry gives a 
mechanistic explanation of the p53 apoptotic inhibition 
in response to drug under hypoxia in those tumors that 
retain a not functional wild-type p53. Thus, for the first 
time, it is shown a direct effect of HIF-1α on HIPK2 
protein stability. Moreover, our findings also open 
novel and unexpected scenarios in tumor development 
and ask to whether HIPK2 might participate to the 
regulation of cancer stem cells (SCs). Hypoxia and 
HIFs-α subunits are considered a critical component of 
a cancer stem cell niche in different tumors including 
glioblastoma [27] and stem-like cells may be integral to 
the development and maintenance of human cancers 
[28]. Our data raise the possibility that HIPK2, because 
of the HIF-1α relationship is involved in the 
homeostasis of cancer SCs and in its subversion in 
tumors. Recent findings showed that loss of p53 favours 
symmetric divisions of cancer SCs, contributing to 
tumor growth [29]. As HIPK2 inhibition negatively 
affects p53 activity [8,30] it would be interesting to 
evaluate whether loss of p53 function in cancer SCs 
depends on HIF-1α-induced HIPK2 inhibition and 
propose an additional mechanism of tumorigenesis. 
Identification of the cell types capable of initiating and 
sustaining growth of the neoplastic clone in vivo is a 
fundamental problem in cancer research. Understanding 
the nature of the more quiescent cancer stem-like cells 
and their niches has the potential to development of 
novel cancer therapeutic protocols including 
pharmacological targeting of self-renewal pathways. 
Therefore, our data strengthen the notion that 
unleashing the growth suppressor activity of both 
HIPK2 and p53 by targeting HIF-1α with zinc is a 
   





Cell culture and treatments. Human patients-derived 
prostate cancer cell lines C38 and C27, [17,31] (kindly 
provided by A. Farsetti, National Research Council, 
Rome, Italy), human embryo kidney 293, were 
maintained in DMEM (Life Technology-Invitrogen), 
while human lung cancer H1299 (p53 null) and colon 
cancer RKO were maintained in RPMI-1640 (Life 
Technology-Invitrogen), all supplemented with 10% 
heat-inactivated fetal bovine serum plus glutamine and 
antibiotics. 
 
Subconfluent cells were treated with adriamycin (ADR) 
diluted into the medium to a final concentration of 1.5 
μg/ml, bleomycin (Bleo) diluted into the medium to a 
final concentration of 120 μM, zinc chloride (ZnCl2) 
diluted into the medium to a final concentration of 100 
μM, or X-ray irradiated with 40 Gy, for the indicated 
period of time. Proteasome inhibitor MG132 at final 
concentration of 10 μM was added for 4 h. 
 
Western blotting and co-immunoprecipitation. Total cell 
extracts and nuclear extracts were prepared essentially 
as described [13]. Proteins were transferred to a 
polyvinylidene difluoride (PVDF) (Millipore) or 
nitrocellulose (Biorad) membranes. Immunoblottings 
were performed with the following antibodies: mouse 
monoclonal anti-HIF-1α, (Novus Biologicals), mouse 
monoclonal anti-p53 (DO1) (Santa Cruz 
Biotechnology), rabbit polyclonal anti-phospho-Ser46, 
(Cell Signaling Technology), rabbit polyclonal anti-
HIPK2 (kindly provided by M.L. Schmitz, Justus-
Liebig-University, Giessen, Germany), mouse 
monoclonal anti-poly(ADP-ribose) polymerase (PARP, 
BD Pharmingen), monoclonal anti-GFP (Roche 
Diagnostic), mouse monoclonal anti-Flag (Sigma), 
mouse monoclonal anti-tubulin (Immunological 
Sciences), and mouse monoclonal anti-Hsp70 
(Stressgene). Immunoreactivity was detected by 
enhanced chemiluminescence kit (ECL; Amersham). 
For HIF-1α/HIPK2 co-immunoprecipitation 293 cells 
were co-transfected with 4 μg HIPK2-GFP and 8 μg 
HIF-1α-Flag expression vector for 24 h. Total cell 
extracts were prepared by incubating at 4
0 C for 30 min 
in lysis buffer (20 mmol/L Hepes, 100 mmol/L NaCl, 5 
mM EDTA (pH 8.0), 10% glicerol). Following 
preclearing for 1 h at 4
0 C, immunoprecipitation was 
performed by incubating total cell extracts with anti-
Flag antibody pre-adsorbed to protein G-Agarose 
(Pierce), rocking for 2 h at 4
0 C. The beads were then 
resuspended in 5x Laemmli buffer and subjected to 
Western blot with the indicated primary antibodies. 
 
RNA extraction and reverse transcription (RT)-PCR 
analysis. Cells were harvested in TRIzol Reagent 
(Invitrogen) and total RNA was isolated following the 
manufacturer’s instructions essentially as described 
[30]. PCR was performed by using gene specific 
oligonucleotides under conditions of linear 
amplification. PCR products were run on a 2% agarose 
gel and visualized by ethidium bromide staining using 
UV light. The housekeeping GAPDH mRNA was used 
as internal control. 
 
Transfection, plasmids and transactivation assay. Cells 
(RKO, C27 C38) were transfected with the cationic 
polymer LipofectaminePlus method (Invitrogen) 
according to manufacturers’ instructions or (293 and 
H1299) with the N,N-bis-(2- hydroxyethyl)-2-amino-
ethanesulphonic acid-buffered saline (BBS) version of 
the calcium phosphate procedure [32]. 
 
For luciferase activity the plasmid reporter used were: 
the HIF-1α-pH800-luc promoter (kindly provided by C. 
Michiels, FUNDP-University of Namur, Belgium), the 
p53-dependent promoters Noxa-luc (kindly provided by 
T. Taniguchi, University of Tokyo, Japan) and 
p53AIP1-luc (kindly provided by H. Arakawa, National 
Cancer Center, Tokyo, Japan). The amount of plasmid 
DNA in each sample was equalized by supplementing 
with empty vector. Transfection efficiency was 
normalized with the use of a co-transfected β-
galactosidase (β-gal) plasmid. Luciferase activity was 
assayed on whole cell extract and the luciferase values 
were normalized to β-galactosidase activity and protein 
content and expressed as relative luciferase unit (RLU). 
The expression vectors used were: the Flag-tagged HIF-
1α and the Flag-tagged HIF-1α with prolyl mutations 
P402A and P564A [33] (kindly provided by G.L. 
Semenza, The Johns Hopkins University School of 
Medicine, Baltimore, MD, USA), the dominant negative 
form of HIF-1α without DNA binding domain and 
transactivation domain (pCEP4-HIF-1αDN) [18] 
(kindly provided by B.H. Jiang, Nanjing Medical 
University, China), HIPK2-GFP [2], pCMV-wtp53, and 
the p53Ser46D (constitutively phosphorylated) (kindly 
provided by Dr. L Mayo, Case Western Reserve 
University, Cleveland, Ohio, USA) mutant. 
 
siRNA interference. Cells were plated at semiconfluence 
in 35 mm dishes the day before transfection. Control-
siRNA and siHIF-1α (Dharmacon) were transfected 
overnight using LipofectaminePlus reagent (Invitrogen) 
and 24 h later cells were trypsinized and replated and 
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luciferase activity. 
 
Chromatin Immunoprecipitation (ChIP) assay. 
Chromatin Immunoprecipitation  (ChIP) analysis was 
carried out essentially as described [30]. Protein 
complexes were cross-linked to DNA in living cells by 
adding formaldehyde directly to the cell vulture 
medium at 1% final concentration. Chromatin extracts 
containing DNA fragments with an average size of 500 
bp were incubated overnight at 4
0 C with milk shaking 
using rabbit polyclonal anti-HIPK2 (Santa Cruz 
Biotechnology) antibody. Before use, protein G (Pierce) 
was blocked with 1 μg/μL sheared herring sperm DNA 
and 1 μg/μL BSA for 3 h at 4
0 C and then incubated 
with chromatin and antibodies for 2 h at 4
0 C. PCR was 
performed with HOT-MASTER Taq (Eppendorf) using 
2 μL of immuniprecipitated DNA and promoter-specific 
primers for human Bcl-2 [26], and CYP1B1 [9] 
promoters. Immunoprecipitation with non-specific 
immunoglobulins (IgG; Santa Cruz Biotechnology) was 
performed as negative controls. The amount of 
precipitated chromatin measured in each PCR was 
normalized with the amount of chromatin present in the 
input of each immunoprecipitation. PCR products were 
run on a 2% agarose gel and visualized by ethidium 
bromide staining using UV light. 
 
TUNEL assay.  For TUNEL assay, 4x10
4 cells were 
spun on a slide by cytocentrifugation and subsequently 
fixed in 4 % paraformaldehyde for 30 min at room 
temperature. After rinsing with PBS the samples were 
permeabilized in a solution of 0.1 % Triton X-100 in 
sodium citrate for 2 min. Samples, washed with PBS, 
were then incubated in the TUNEL reaction mix for 1 h 
at 37
0C, according to the manufacturer’s instructions 
(Roche, Germany). Cells were counter-stained with 
Hoechst 33342 before analysis  with a fluorescent 
microscope (Zeiss). Standard deviations of three 
independent experiments were indicated. 
 
Statistics. All experiment unless indicated were 
performed at least three times. All experimental results 
were expressed as the arithmetic mean and standard 
deviation (s.d.) of measurements was shown. Student’s 
t-test was used for statistical significance of the 
differences between treatment groups. Statistical 
analysis was performed using analysis of variance at 5% 
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Similar  result  was  obtained  in  C27  cells  by  RT‐PCR  analysis  where  zinc  restored  the  p53
apoptotic  gene  transcription  in  response  to  bleomycin  (Bleo).  GAPDH  was  used  as  internal
control.  (c)  Tunel  assay  of  C27  cells  showing  increased  apoptotic  cell  death  only  after  zinc








total  input  chromatin  (Input)  was  included  as  control.  Additional  controls
included  immunoprecipitation  performed  with  non‐specific  immunoglobulins
(No Ab). 
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